Skip To Main

REPS. CLARKE AND BROWN HOLD PRESS CONFERENCE TO ANNOUNCE UTERINE CANCER STUDY LEGISLATION

FOR IMMEDIATE RELEASE:

September 24, 2024

MEDIA CONTACT: 

e: jessica.myers@mail.house.gov

c: 202.913.0126

Washington, DC — Today, Congresswoman Yvette D. Clarke (NY-09) and Congresswoman Shontel Brown (OH-11) held a press conference on Capitol Hill to announce their joint legislation, the Uterine Cancer Study Act. This bill would require the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the National Institute of Health (NIH) to coordinate and conduct a study on the relationship between hair straighteners and uterine cancer. 

Recent studies have discovered that women who have used chemical hair straightening products are at higher risk for uterine cancer than those who have not – risks associated with and particularly higher in Black women.

This study is vital to preserving the lives of those impacted by: 

  • Reviewing significant findings and recommendations from other studies regarding the relationship between hair straighteners and uterine cancer.
  • Considering the impacts on women and other individuals at risk of uterine cancer.
  • Disaggregating the results of the study according to whether the hair straighteners contain dyes or coloring, bleach highlights, or perms.
  • Determining whether the FDA should impose additional testing requirements on manufacturers of hair straightening products.
  • Focusing on the increased incidences of such cancer among women of color. 

“Like many other Black women who have used hair straightening products, I was unaware of the potential connection and harmful impacts these chemicals would have on our overall health – putting me and other women of color at a higher risk for uterine cancer, the most common cancer related to the female reproductive system,” said Congresswoman Yvette D. Clarke. “We need more research to fully understand the relationship between perms and uterine cancer. This legislation will address the detrimental effects of chemicals within hair straighteners on women’s health and hopefully, lead the FDA towards requiring manufacturers to test for cancer-causing chemicals.”

“The research supported by the Uterine Cancer Study Act is sorely needed to identify environmental and chemical factors contributing to the racial disparities associated with uterine cancer. By investigating the connection between those factors and cancer, we can create a path toward more informed choices and better health outcomes for Black women. I am proud to join Congresswoman Clarke and champion this vital legislation,” said Congresswoman Shontel Brown.

“Beauty standards for years demanded that our hair be straight, but we can’t help the way it grows out of our heads,” said Rep. Bonnie Watson Coleman. “Chemical hair straighteners have been linked to a variety of harmful hormone-related health outcomes — including higher instances of uterine cancer. Despite this, we still know very little about the long-term health risks that these products pose. That’s why my sister, Rep. Clarke’s bill to study the relationship between these hair products and uterine cancer is so important. We need to equip ourselves with the information to make safe choices. I strongly encourage the House to pass this crucial legislation.”

“A recent NIH study stated that more than 4% of women with uterine cancer reported use of chemical straighteners, compared to the 1% of women who did not use these products,” said Congressman Gregory W. Meeks. “Chemical relaxers have long been a part of Black Beauty and Hair Care; as a result, these purported adverse health effects disproportionately impact Black women. We need to deploy all of our available federal resources to better study and understand the real health implications on women of color. As a husband and father, I am proud to co-sponsor the Uterine Cancer Study Act of 2024.”

“Black women have been systematically left out of conversations and decisions about their own health. Women of color and our unique experiences have historically been underrepresented in research, leading to adverse health outcomes,” said Congresswoman Robin Kelly. “We cannot allow the status quo to continue. I’m proud to co-sponsor the Uterine Cancer Study Act to address the gap in knowledge between uterine cancer and hair products. Black women deserve to take care of our hair without being exposed to toxic ingredients that increase our already heightened risk of cancer.”

“A woman’s uterus is a sacred place. It should be the source of new birth, joy, and family, not pain or suffering. I am calling on Congress to accelerate the research on Uterine Cancer, to find out why women of color experience it at elevated rates and to discover treatments and preventative care. Let’s not politicize women’s health. We’re all in this together,” said Congresswoman Alma Adams.

“As a Black woman, I understand how deeply rooted hair care is in our community. Many of us were introduced to hair straighteners as young girls, unaware of the risks, said Congresswoman Beatty. Now, it’s vital that we investigate the troubling relationship between these products and uterine cancer. The Uterine Cancer Study Act of 2024 will bring critical research and coordination to uncover the dangers and push for solutions that can save lives. Our community deserves answers, and this bill is a vital step to protecting ourselves and our daughters,” said Congresswoman Joyce Beatty.

“Let’s prioritize research to better understand and diagnose uterine cancer. Uterine bleeding and uterine pain should not be categorically dismissed as normal,” said Sateria Venable, CEO, The Fibroid Foundation.

“Women of color are being sold hair straighteners that should come with a cancer warning. We now know that women who have used chemical hair straightening products are at higher risk for uterine cancer than those who have not. However, more research is needed to understand this connection better, and the Uterine Cancer Study Act of 2024 will make determining how environmental factors contribute to these racial disparities a federal priority. Women of color’s health and livelihood need—and deserve—nothing less,” said Christian F. Nunes, National President, National Organization for Women.

“We want to thank Congresswoman Yvette Clarke and Shontel Brown for their leadership in introducing the Uterine Cancer Study Act of 2024. Black women are at higher risk of uterine cancer, and comprehensive action is needed so that we know definitively why this is the case. We support efforts that improve research and education on uterine cancer and believe Black women should be partners in the research process,” said Zsanai Epps, DrPH, MPH, CHES, Senior Director, Reproductive Justice Initiatives, Black Women’s Health Imperative.

“As the Executive Director of the Mississippi Black Women’s Roundtable, I commend Brooklyn Congresswoman Yvette Clarke and her colleagues for championing the Uterine Cancer Study Act 2024. This legislation promises crucial advancements in addressing the disparities in uterine cancer research and care, particularly affecting Black women, and we fully endorse its passage,” said Tomika Anderson, Executive Director, Mississippi Black Women’s Roundtable.

The Uterine Cancer Study Act is co-sponsored by Reps. Adams, Beatty, Blunt Rochester, Cherfilus-McCormick, Crockett, Don Davis, Fletcher, Foushee, Holmes Norton, Kelly, Lee, Lofgren, McBath, McClellan, Meeks, Plaskett, Sewell, Stanford, T Carter Sr., Tonko, Velázquez, Watson-Coleman, N. Williams, Wilson, and Wasserman Schultz.

The Uterine Cancer Study Act is endorsed by the Black Women’s Health Imperative, Society for Women’s Health Research, National Organization for Women, The Fibroid Foundation, The White Dress Project, Mississippi Black Women’s Roundtable, MANA – A National Latina Organization, National Coalition on Black Civic Participation, Pro-Choice North Carolina, Sisters in Loss Foundation, National Women’s Health Network.

Read the full bill text here.

###